Emergent Biosolutions Inc. (NYSE:EBS) Stock Has Consensus Price Target of $10.00

Key Points

• Analysts have a consensus “Hold” rating on Emergent BioSolutions, with two sell, one hold, and three buy recommendations. The average 12-month price target is $10.00, compared with the stock’s opening price of $6.33.
• Institutional investors and hedge funds own 78.4% of the company, while several investment firms recently initiated positions in Emergent BioSolutions.
• The company exceeded quarterly expectations, reporting adjusted EPS of $0.60 versus estimates of a $0.08 loss and revenue of $234.3 million versus the $177.5 million consensus estimate. Despite the earnings beat, Emergent posted a negative net margin of 22.95%.

Emergent Biosolutions Inc. (NYSE:EBS - Get Free Report) has received an average recommendation of "Hold" from the six analysts that are currently covering the stock, MarketBeat reports. Two equities research analysts have rated the stock with a sell recommendation, one has issued a hold recommendation and three have given a buy recommendation to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $10.00.

Several equities research analysts have recently commented on EBS shares. Zacks Research upgraded shares of Emergent Biosolutions to a "hold" rating in a research note on Tuesday, August 11th. JPMorgan Chase & Co. assumed coverage on shares of Emergent Biosolutions in a research report on Friday, August 21st. They set an "underweight" rating for the company. HC Wainwright restated a "buy" rating and issued a $10.00 price target on shares of Emergent Biosolutions in a research report on Wednesday, September 9th. Finally, Weiss Ratings upgraded shares of Emergent Biosolutions from a "sell (d-)" rating to a "sell (d)" rating in a research report on Friday, August 21st.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. Integrated Wealth Concepts LLC acquired a new stake in Emergent Biosolutions during the 2nd quarter valued at $29,000. Public Employees Retirement System of Ohio acquired a new position in Emergent Biosolutions in the second quarter worth $36,000. Legal & General Group Plc acquired a new position in Emergent Biosolutions in the second quarter worth $44,000. Tocqueville Asset Management L.P. bought a new stake in shares of Emergent Biosolutions during the second quarter worth $93,000. Finally, The Manufacturers Life Insurance Company bought a new stake in shares of Emergent Biosolutions during the second quarter worth $115,000. 78.40% of the stock is owned by institutional investors and hedge funds.

Emergent Biosolutions Price Performance

Emergent Biosolutions stock opened at $6.33 on Monday. The company has a debt-to-equity ratio of 1.70, a current ratio of 5.42 and a quick ratio of 2.95. The company has a market capitalization of $324.28 million, a PE ratio of -1.78 and a beta of 2.28. Emergent Biosolutions has a one year low of $4.36 and a one year high of $14.06. The business has a 50 day simple moving average of $6.11 and a 200 day simple moving average of $7.49.

Emergent Biosolutions (NYSE:EBS - Get Free Report) last announced its quarterly earnings results on Wednesday, August 5th. The biopharmaceutical company reported $0.60 EPS for the quarter, beating the consensus estimate of ($0.08) by $0.68. Emergent Biosolutions had a positive return on equity of 16.35% and a negative net margin of 22.95%.The business had revenue of $234.30 million for the quarter, compared to analyst estimates of $177.50 million. On average, sell-side analysts forecast that Emergent Biosolutions will post 0.13 EPS for the current fiscal year.

About Emergent Biosolutions

Emergent BioSolutions Inc NYSE: EBS is a life sciences company focused on developing, manufacturing and supplying medical countermeasures for public health threats, including chemical, biological, radiological and nuclear hazards, as well as infectious diseases. The company serves government agencies, healthcare providers and commercial customers.

Emergent's portfolio has included vaccines, therapeutics and other products used to prevent or treat serious health threats. Its offerings include BioThrax, an anthrax vaccine, and ACAM2000, a smallpox vaccine, along with products such as botulism antitoxin and vaccinia immune globulin.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.